Your session is about to expire
← Back to Search
Anti-tumor antibiotic, Anti-metabolites
CLAG-M for Lymphoblastic Lymphoma
Phase 2
Waitlist Available
Led By Karen Seiter, MD
Research Sponsored by New York Medical College
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Relapsed or refractory acute lymphoblastic leukemia
Burkitts leukemia/lymphoma
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Study Summary
CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the efficacy of the regimen in patients with relapsed ALL.
Eligible Conditions
- Lymphoblastic Lymphoma
- Burkitt Lymphoma
- Leukemia
- Acute Lymphoblastic Leukemia
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Complete remission percentage
Secondary outcome measures
Survival
Trial Design
1Treatment groups
Experimental Treatment
Group I: CLAG-MExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
New York Medical CollegeLead Sponsor
69 Previous Clinical Trials
5,961 Total Patients Enrolled
Karen Seiter, MDPrincipal InvestigatorNew York Medical College
1 Previous Clinical Trials
100 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger